Stephen Foster and associates have published a paper on Treatment of Birdshot with Infliximab. You may be aware that Stephen Foster is hosting the 2013 Birdshot Day on 28 September 2013, in Boston, United States. He has a profound interest in Birdshot and was instrumental in helping us set up BUS.
The group looked at 22 people (44 eyes) who had received infliximab (as opposed to conventional immunomodulatory therapies) between July 2005 and June 2012. The patients had had Birdshot for a mean of just under 5 years and they had all tried conventional therapies which did not work for them. Ten of these patients had also used a biologic agent without success.
After starting on infliximab, 81.8% of patients had achieved a control of the inflammation within 6 months and 88.9% by one year. Macular oedema was also reduced from 22.7% at the start of receiving infliximab to 13.9% at 6 months. In addition, after 1 year, 94.4% of eyes (the 44 eyes of 22 patients) had a visual acuity of 20/40 or better.
6 patients had adverse reactions, and infliximab had to be discontinued.
The conclusion is that infliximab can be effective at controlling inflammation in people who do not do well on conventional immunomodulatory therapies.
Read the full text at: